First Header Logo Second Header Logo

Pierre L. Triozzi MD

TitleProfessor
InstitutionWake Forest School of Medicine
DepartmentInternal Medicine, Hematology & Oncology
Address
vCardDownload vCard
    Other Positions
    TitleProfessor
    InstitutionWake Forest School of Medicine
    DepartmentCancer Biology


    Collapse Research 
    Collapse research activities and funding
    R01CA067830     (TRIOZZI, PIERRE L)Aug 1, 1995 - Jan 31, 2000
    NIH
    ANTIGEN PULSED DENDRITIC CELL IMMUNOTHERAPY
    Role: Principal Investigator
    R21CA082869     (TRIOZZI, PIERRE L)Sep 1, 1999 - Aug 31, 2002
    NIH
    CHIMERIC HER-2 PEPTIDE VACCINE
    Role: Principal Investigator
    R21CA089925     (TRIOZZI, PIERRE L)Aug 16, 2001 - May 31, 2004
    NIH
    Intratumoral Dendritic Cells Plus Interleukin-2
    Role: Principal Investigator
    R01CA118660     (TRIOZZI, PIERRE L)Aug 1, 2006 - Jul 31, 2012
    NIH
    AAV-Based Plasmacytoid Dendritic Cell Cancer Vaccine
    Role: Principal Investigator
    R01CA136776     (TRIOZZI, PIERRE L)Aug 15, 2009 - Jul 31, 2011
    NIH
    Uveal Melanoma Micrometastasis
    Role: Principal Investigator
    R21CA175671     (TRIOZZI, PIERRE L)Dec 1, 2013 - Nov 30, 2016
    NIH
    Differentiation Therapy of Uveal Melanoma Micrometastases
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Helis CA, Hughes RT, Glenn CW, Lanier CM, Masters AH, Dohm A, Ahmed T, Ruiz J, Triozzi P, Gondal H, Cramer CK, Tatter SB, Laxton AW, Xing F, Lo HW, Su J, Watabe K, Wang G, Whitlow CT, Chan MD. Predictors of Adverse Radiation Effect in Brain Metastasis Patients Treated With Stereotactic Radiosurgery and Immune Checkpoint Inhibitor Therapy. Int J Radiat Oncol Biol Phys. 2020 09 01; 108(1):295-303. PMID: 32615262.
      Citations:    
    2. Votanopoulos KI, Forsythe S, Sivakumar H, Mazzocchi A, Aleman J, Miller L, Levine E, Triozzi P, Skardal A. Model of Patient-Specific Immune-Enhanced Organoids for Immunotherapy Screening: Feasibility Study. Ann Surg Oncol. 2020 Jun; 27(6):1956-1967. PMID: 31858299.
      Citations:    
    3. Soike MH, Logue J, Qasem S, Hughes RT, McTyre E, Su J, Triozzi P, Bendandi M, Lo HW, Ahmed T, O'Neill SS, Debinski W, Pasche B, Watabe K, Miller LD, Chan MD, Ruiz J. CD138 plasma cells may predict brain metastasis recurrence following resection and stereotactic radiosurgery. Sci Rep. 2019 10 07; 9(1):14385. PMID: 31591443.
      Citations:    
    4. Binkley E, Triozzi PL, Rybicki L, Achberger S, Aldrich W, Singh A. A prospective trial of adjuvant therapy for high-risk uveal melanoma: assessing 5-year survival outcomes. Br J Ophthalmol. 2020 04; 104(4):524-528. PMID: 31371315.
      Citations:    
    5. Tafreshi NK, Tichacek CJ, Pandya DN, Doligalski ML, Budzevich MM, Kil H, Bhatt NB, Kock ND, Messina JL, Ruiz EE, Delva NC, Weaver A, Gibbons WR, Boulware DC, Khushalani NI, El-Haddad G, Triozzi PL, Moros EG, McLaughlin ML, Wadas TJ, Morse DL. Melanocortin 1 Receptor-Targeted a-Particle Therapy for Metastatic Uveal Melanoma. J Nucl Med. 2019 08; 60(8):1124-1133. PMID: 30733316.
      Citations:    
    6. Lanier CM, Hughes R, Ahmed T, LeCompte M, Masters AH, Petty WJ, Ruiz J, Triozzi P, Su J, O'Neill S, Watabe K, Cramer CK, Laxton AW, Tatter SB, Wang G, Whitlow C, Chan MD. Immunotherapy is associated with improved survival and decreased neurologic death after SRS for brain metastases from lung and melanoma primaries. Neurooncol Pract. 2019 Sep; 6(5):402-409. PMID: 31555455.
      Citations:    
    7. Bonomi M, Ahmed T, Addo S, Kooshki M, Palmieri D, Levine BJ, Ruiz J, Grant S, Petty WJ, Triozzi PL. Circulating immune biomarkers as predictors of the response to pembrolizumab and weekly low dose carboplatin and paclitaxel in NSCLC and poor PS: An interim analysis. Oncol Lett. 2019 Jan; 17(1):1349-1356. PMID: 30655905.
      Citations:    
    8. Raj S, Miller LD, Triozzi PL. Addressing the Adult Soft Tissue Sarcoma Microenvironment with Intratumoral Immunotherapy. Sarcoma. 2018; 2018:9305294. PMID: 30158830.
      Citations:    
    9. Thomas A, Routh ED, Pullikuth A, Jin G, Su J, Chou JW, Hoadley KA, Print C, Knowlton N, Black MA, Demaria S, Wang E, Bedognetti D, Jones WD, Mehta GA, Gatza ML, Perou CM, Page DB, Triozzi P, Miller LD. Tumor mutational burden is a determinant of immune-mediated survival in breast cancer. Oncoimmunology. 2018; 7(10):e1490854. PMID: 30386679.
      Citations:    
    10. Chesney J, Awasthi S, Curti B, Hutchins L, Linette G, Triozzi P, Tan MCB, Brown RE, Nemunaitis J, Whitman E, Windham C, Lutzky J, Downey GF, Batty N, Amatruda T. Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma. Melanoma Res. 2018 02; 28(1):44-51. PMID: 29176501.
      Citations:    
    11. Bhatt NB, Pandya DN, Dezarn WA, Marini FC, Zhao D, Gmeiner WH, Triozzi PL, Wadas TJ. Practical Guidelines for Cerenkov Luminescence Imaging with Clinically Relevant Isotopes. Methods Mol Biol. 2018; 1790:197-208. PMID: 29858793.
      Citations:    
    12. LeCompte MC, McTyre E, Henson A, Farris M, Okoukoni C, Cramer CK, Triozzi P, Ruiz J, Watabe K, Lo HW, Munley MT, Laxton AW, Tatter SB, Zhou X, Chan M. Survival and Failure Outcomes Predicted by Brain Metastasis Volumetric Kinetics in Melanoma Patients Following Upfront Treatment with Stereotactic Radiosurgery Alone. Cureus. 2017 Dec 11; 9(12):e1934. PMID: 29464141.
      Citations:    
    13. Soto-Pantoja DR, Wilson AS, Clear KY, Westwood B, Triozzi PL, Cook KL. Unfolded protein response signaling impacts macrophage polarity to modulate breast cancer cell clearance and melanoma immune checkpoint therapy responsiveness. Oncotarget. 2017 Oct 06; 8(46):80545-80559. PMID: 29113324.
      Citations:    
    14. Joshi P, Kooshki M, Aldrich W, Varghai D, Zborowski M, Singh AD, Triozzi PL. Expression of natural killer cell regulatory microRNA by uveal melanoma cancer stem cells. Clin Exp Metastasis. 2016 12; 33(8):829-838. PMID: 27565163.
      Citations:    
    15. Triozzi PL, Achberger S, Aldrich W, Crabb JW, Saunthararajah Y, Singh AD. Association of tumor and plasma microRNA expression with tumor monosomy-3 in patients with uveal melanoma. Clin Epigenetics. 2016; 8:80. PMID: 27453764.
      Citations:    
    16. Schuermeyer I, Maican A, Sharp R, Bena J, Triozzi PL, Singh AD. Depression, Anxiety, and Regret Before and After Testing to Estimate Uveal Melanoma Prognosis. JAMA Ophthalmol. 2016 Jan; 134(1):51-6. PMID: 26539659.
      Citations:    
    17. Triozzi PL, Aldrich W, Crabb JW, Singh AD. Spontaneous cellular and humoral tumor antigen responses in patients with uveal melanoma. Melanoma Res. 2015 Dec; 25(6):510-8. PMID: 26397048.
      Citations:    
    18. Crabb JW, Hu B, Crabb JS, Triozzi P, Saunthararajah Y, Tubbs R, Singh AD. iTRAQ Quantitative Proteomic Comparison of Metastatic and Non-Metastatic Uveal Melanoma Tumors. PLoS One. 2015; 10(8):e0135543. PMID: 26305875.
      Citations:    
    19. Singh AD, Medina CA, Singh N, Aronow ME, Biscotti CV, Triozzi PL. Fine-needle aspiration biopsy of uveal melanoma: outcomes and complications. Br J Ophthalmol. 2016 Apr; 100(4):456-62. PMID: 26231747.
      Citations:    
    20. Choudhary MM, Triozzi PL, Singh AD. Uveal melanoma: evidence for adjuvant therapy. Int Ophthalmol Clin. 2015; 55(1):45-51. PMID: 25436492.
      Citations:    
    21. Triozzi PL, Schoenfield L, Plesec T, Saunthararajah Y, Tubbs RR, Singh AD. Molecular profiling of primary uveal melanomas with tumor-infiltrating lymphocytes. Oncoimmunology. 2019; 8(10):e947169. PMID: 31646061.
      Citations:    
    22. Triozzi PL, Singh AD. Adjuvant Therapy of Uveal Melanoma: Current Status. Ocul Oncol Pathol. 2014 Oct; 1(1):54-62. PMID: 27175362.
      Citations:    
    23. Luke JJ, Triozzi PL, McKenna KC, Van Meir EG, Gershenwald JE, Bastian BC, Gutkind JS, Bowcock AM, Streicher HZ, Patel PM, Sato T, Sossman JA, Sznol M, Welch J, Thurin M, Selig S, Flaherty KT, Carvajal RD. Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell Melanoma Res. 2015 Mar; 28(2):135-47. PMID: 25113308.
      Citations:    
    24. Minca EC, Tubbs RR, Portier BP, Wang Z, Lanigan C, Aronow ME, Triozzi PL, Singh A, Cook JR, Saunthararajah Y, Plesec TP, Schoenfield L, Cawich V, Sulpizio S, Schultz RA. Genomic microarray analysis on formalin-fixed paraffin-embedded material for uveal melanoma prognostication. Cancer Genet. 2014 Jul-Aug; 207(7-8):306-15. PMID: 25442074.
      Citations:    
    25. Mittal K, Koon H, Elson P, Triozzi P, Dowlati A, Chen H, Borden EC, Rini BI. Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkers. . 2014 Aug; 15(8):975-81. PMID: 24842548.
      Citations:    
    26. Joshi P, Jacobs B, Derakhshan A, Moore LR, Elson P, Triozzi PL, Borden E, Zborowski M. Enrichment of circulating melanoma cells (CMCs) using negative selection from patients with metastatic melanoma. Oncotarget. 2014 May 15; 5(9):2450-61. PMID: 24811334.
      Citations:    
    27. Achberger S, Aldrich W, Tubbs R, Crabb JW, Singh AD, Triozzi PL. Circulating immune cell and microRNA in patients with uveal melanoma developing metastatic disease. Mol Immunol. 2014 Apr; 58(2):182-6. PMID: 24370793.
      Citations:    
    28. Joshi P, Zborowski M, Triozzi PL. Circulating melanoma cells: scoping the target. Front Oncol. 2013; 3:189. PMID: 23964346.
      Citations:    
    29. Brenner AJ, Cohen YC, Breitbart E, Bangio L, Sarantopoulos J, Giles FJ, Borden EC, Harats D, Triozzi PL. Phase I dose-escalation study of VB-111, an antiangiogenic virotherapy, in patients with advanced solid tumors. Clin Cancer Res. 2013 Jul 15; 19(14):3996-4007. PMID: 23589178.
      Citations:    
    30. Garcia JA, Elson P, Tyler A, Triozzi P, Dreicer R. Sargramostim (GM-CSF) and lenalidomide in castration-resistant prostate cancer (CRPC): results from a phase I-II clinical trial. Urol Oncol. 2014 Jan; 32(1):33.e11-7. PMID: 23510862.
      Citations:    
    31. Triozzi PL, Fernandez AP. The role of the immune response in merkel cell carcinoma. Cancers (Basel). 2013 Feb 28; 5(1):234-54. PMID: 24216706.
      Citations:    
    32. Triozzi PL, Elson P, Aldrich W, Achberger S, Tubbs R, Biscotti CV, Singh AD. Elevated blood ß-2 microglobulin is associated with tumor monosomy-3 in patients with primary uveal melanoma. Melanoma Res. 2013 Feb; 23(1):1-7. PMID: 23196330.
      Citations:    
    33. Triozzi PL, Achberger S, Aldrich W, Singh AD, Grane R, Borden EC. The association of blood angioregulatory microRNA levels with circulating endothelial cells and angiogenic proteins in patients receiving dacarbazine and interferon. J Transl Med. 2012 Dec 05; 10:241. PMID: 23217102.
      Citations:    
    34. Triozzi PL, Achberger S, Aldrich W, Elson P, Garcia J, Dreicer R. Differential immunologic and microRNA effects of 2 dosing regimens of recombinant human granulocyte/macrophage colony stimulating factor. J Immunother. 2012 Sep; 35(7):587-94. PMID: 22892455.
      Citations:    
    35. Singh AD, Aronow ME, Sun Y, Bebek G, Saunthararajah Y, Schoenfield LR, Biscotti CV, Tubbs RR, Triozzi PL, Eng C. Chromosome 3 status in uveal melanoma: a comparison of fluorescence in situ hybridization and single-nucleotide polymorphism array. Invest Ophthalmol Vis Sci. 2012 Jun 05; 53(7):3331-9. PMID: 22511634.
      Citations:    
    36. Aronow M, Sun Y, Saunthararajah Y, Biscotti C, Tubbs R, Triozzi P, Singh AD. Monosomy 3 by FISH in uveal melanoma: variability in techniques and results. Surv Ophthalmol. 2012 Sep; 57(5):463-73. PMID: 22658782.
      Citations:    
    37. Triozzi PL, Aldrich W, Achberger S, Ponnazhagan S, Alcazar O, Saunthararajah Y. Differential effects of low-dose decitabine on immune effector and suppressor responses in melanoma-bearing mice. Cancer Immunol Immunother. 2012 Sep; 61(9):1441-50. PMID: 22310929.
      Citations:    
    38. Triozzi PL, Singh AD. Blood biomarkers for uveal melanoma. Future Oncol. 2012 Feb; 8(2):205-15. PMID: 22335584.
      Citations:    
    39. Saunthararajah Y, Triozzi P, Rini B, Singh A, Radivoyevitch T, Sekeres M, Advani A, Tiu R, Reu F, Kalaycio M, Copelan E, Hsi E, Lichtin A, Bolwell B. p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies. Semin Oncol. 2012 Feb; 39(1):97-108. PMID: 22289496.
      Citations:    
    40. Yi T, Elson P, Mitsuhashi M, Jacobs B, Hollovary E, Budd TG, Spiro T, Triozzi P, Borden EC. Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects. Oncotarget. 2011 Dec; 2(12):1155-64. PMID: 22201704.
      Citations:    
    41. Triozzi PL, Borden EC. VB-111 for cancer. Expert Opin Biol Ther. 2011 Dec; 11(12):1669-76. PMID: 21961496.
      Citations:    
    42. Alcazar O, Achberger S, Aldrich W, Hu Z, Negrotto S, Saunthararajah Y, Triozzi P. Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo. Int J Cancer. 2012 Jul 01; 131(1):18-29. PMID: 21796622.
      Citations:    
    43. Triozzi PL, Aldrich W, Singh A. Effects of interleukin-1 receptor antagonist on tumor stroma in experimental uveal melanoma. Invest Ophthalmol Vis Sci. 2011 Jul 25; 52(8):5529-35. PMID: 21519029.
      Citations:    
    44. Triozzi PL, Tuthill RJ, Borden E. Re-inventing intratumoral immunotherapy for melanoma. Immunotherapy. 2011 May; 3(5):653-71. PMID: 21554094.
      Citations:    
    45. Schwandt A, Garcia JA, Elson P, Wyckhouse J, Finke JH, Ireland J, Triozzi P, Zhou M, Dreicer R, Rini BI. Clinical and immunomodulatory effects of celecoxib plus interferon-alpha in metastatic renal cell carcinoma patients with COX-2 tumor immunostaining. J Clin Immunol. 2011 Aug; 31(4):690-8. PMID: 21487892.
      Citations:    
    46. Negrotto S, Hu Z, Alcazar O, Ng KP, Triozzi P, Lindner D, Rini B, Saunthararajah Y. Noncytotoxic differentiation treatment of renal cell cancer. Cancer Res. 2011 Feb 15; 71(4):1431-41. PMID: 21303982.
      Citations:    
    47. Borden EC, Jacobs B, Hollovary E, Rybicki L, Elson P, Olencki T, Triozzi P. Gene regulatory and clinical effects of interferon ß in patients with metastatic melanoma: a phase II trial. J Interferon Cytokine Res. 2011 May; 31(5):433-40. PMID: 21235385.
      Citations:    
    48. Triozzi PL, Singh AD. Blood biomarkers of uveal melanoma metastasis. Br J Ophthalmol. 2011 Jan; 95(1):3-4. PMID: 21163819.
      Citations:    
    49. Torres V, Triozzi P, Eng C, Tubbs R, Schoenfiled L, Crabb JW, Saunthararajah Y, Singh AD. Circulating tumor cells in uveal melanoma. Future Oncol. 2011 Jan; 7(1):101-9. PMID: 21174541.
      Citations:    
    50. Triozzi PL, Aldrich W, Ponnazhagan S. Regulation of the activity of an adeno-associated virus vector cancer vaccine administered with synthetic Toll-like receptor agonists. Vaccine. 2010 Nov 23; 28(50):7837-43. PMID: 20937315.
      Citations:    
    51. Garcia JA, Mekhail T, Elson P, Triozzi P, Nemec C, Dreicer R, Bukowski RM, Rini BI. Clinical and immunomodulatory effects of bevacizumab and low-dose interleukin-2 in patients with metastatic renal cell carcinoma: results from a phase II trial. BJU Int. 2011 Feb; 107(4):562-70. PMID: 20840548.
      Citations:    
    52. Triozzi PL, Aldrich W. Effects of interleukin-1 receptor antagonist and chemotherapy on host-tumor interactions in established melanoma. Anticancer Res. 2010 Feb; 30(2):345-54. PMID: 20332438.
      Citations:    
    53. Rini BI, Garcia JA, Cooney MM, Elson P, Tyler A, Beatty K, Bokar J, Mekhail T, Bukowski RM, Budd GT, Triozzi P, Borden E, Ivy P, Chen HX, Dolwati A, Dreicer R. A phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin Cancer Res. 2009 Oct 01; 15(19):6277-83. PMID: 19773375.
      Citations:    
    54. Triozzi PL, Aldrich W, Dombos C. Differential effects of imatinib mesylate against uveal melanoma in vitro and in vivo. Melanoma Res. 2008 Dec; 18(6):420-30. PMID: 18971787.
      Citations:    
    55. Garcia JA, Klein EA, Magi-Galluzzi C, Elson P, Triozzi P, Dreicer R. Clinical and biological effects of neoadjuvant sargramostim and thalidomide in patients with locally advanced prostate carcinoma. Clin Cancer Res. 2008 May 15; 14(10):3052-9. PMID: 18483371.
      Citations:    
    56. Triozzi PL, Eng C, Singh AD. Targeted therapy for uveal melanoma. Cancer Treat Rev. 2008 May; 34(3):247-58. PMID: 18226859.
      Citations:    
    57. Triozzi PL, Shah JJ, Wang WQ, Aldrich W, Edberg JC, Su K, Carlisle R, Conry R, LoBuglio AF, Forero A. Anti-GD3 monoclonal antibody effects on lymphocytes and antibody-dependent cellular cytotoxicity. Cancer Biother Radiopharm. 2006 Dec; 21(6):553-60. PMID: 17257070.
      Citations:    
    58. Forero A, Shah J, Carlisle R, Triozzi PL, LoBuglio AF, Wang WQ, Fujimori M, Conry RM. A phase I study of an anti-GD3 monoclonal antibody, KW-2871, in patients with metastatic melanoma. Cancer Biother Radiopharm. 2006 Dec; 21(6):561-8. PMID: 17257071.
      Citations:    
    59. Wakchoure S, Merrell MA, Aldrich W, Millender-Swain T, Harris KW, Triozzi P, Selander KS. Bisphosphonates inhibit the growth of mesothelioma cells in vitro and in vivo. Clin Cancer Res. 2006 May 01; 12(9):2862-8. PMID: 16675582.
      Citations:    
    60. Triozzi PL, Bolger GB, Neidhart J, Rinehart JJ, Saleh M, Allen KO, Sellers S, Waddell MJ. Effect of docetaxel chemotherapy on the activity of a gonadotropin releasing hormone vaccine in patients with advanced prostate cancer. Prostate. 2005 Dec 01; 65(4):316-21. PMID: 16015596.
      Citations:    
    61. Triozzi PL, Aldrich W, Allen KO, Carlisle RR, LoBuglio AF, Conry RM. Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected melanoma at risk for relapse. J Immunother. 2005 Jul-Aug; 28(4):382-8. PMID: 16000957.
      Citations:    
    62. Triozzi PL, Allen KO, Carlisle RR, Craig M, LoBuglio AF, Conry RM. Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma. Clin Cancer Res. 2005 Jun 01; 11(11):4168-75. PMID: 15930353.
      Citations:    
    63. Korokhov N, de Gruijl TD, Aldrich WA, Triozzi PL, Banerjee PT, Gillies SD, Curiel TJ, Douglas JT, Scheper RJ, Curiel DT. High efficiency transduction of dendritic cells by adenoviral vectors targeted to DC-SIGN. . 2005 Mar; 4(3):289-94. PMID: 15753654.
      Citations:    
    64. Lima J, Jenkins C, Guerrero A, Triozzi PL, Shaw DR, Strong TV. A DNA vaccine encoding genetic fusions of carcinoembryonic antigen (CEA) and granulocyte/macrophage colony-stimulating factor (GM-CSF). Vaccine. 2005 Jan 26; 23(10):1273-83. PMID: 15652670.
      Citations:    
    65. Triozzi PL, Aldrich W, Allen KO, Lima J, Shaw DR, Strong TV. Antitumor activity of the intratumoral injection of fowlpox vectors expressing a triad of costimulatory molecules and granulocyte/macrophage colony stimulating factor in mesothelioma. Int J Cancer. 2005 Jan 20; 113(3):406-14. PMID: 15455351.
      Citations:    
    66. Triozzi PL, Strong TV, Bucy RP, Allen KO, Carlisle RR, Moore SE, Lobuglio AF, Conry RM. Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic melanoma. Hum Gene Ther. 2005 Jan; 16(1):91-100. PMID: 15703492.
      Citations:    
    67. Ponnazhagan S, Mahendra G, Lima J, Aldrich WA, Jenkins CB, Ren C, Kumar S, Kallman L, Strong TV, Shaw DR, Triozzi PL. Augmentation of antitumor activity of a recombinant adeno-associated virus carcinoembryonic antigen vaccine with plasmid adjuvant. Hum Gene Ther. 2004 Sep; 15(9):856-64. PMID: 15353040.
      Citations:    
    68. Pereboev AV, Nagle JM, Shakhmatov MA, Triozzi PL, Matthews QL, Kawakami Y, Curiel DT, Blackwell JL. Enhanced gene transfer to mouse dendritic cells using adenoviral vectors coated with a novel adapter molecule. Mol Ther. 2004 May; 9(5):712-20. PMID: 15120332.
      Citations:    
    69. Neidhart J, Allen KO, Barlow DL, Carpenter M, Shaw DR, Triozzi PL, Conry RM. Immunization of colorectal cancer patients with recombinant baculovirus-derived KSA (Ep-CAM) formulated with monophosphoryl lipid A in liposomal emulsion, with and without granulocyte-macrophage colony-stimulating factor. Vaccine. 2004 Jan 26; 22(5-6):773-80. PMID: 14741172.
      Citations:    
    70. Korokhov N, Mikheeva G, Krendelshchikov A, Belousova N, Simonenko V, Krendelshchikova V, Pereboev A, Kotov A, Kotova O, Triozzi PL, Aldrich WA, Douglas JT, Lo KM, Banerjee PT, Gillies SD, Curiel DT, Krasnykh V. Targeting of adenovirus via genetic modification of the viral capsid combined with a protein bridge. J Virol. 2003 Dec; 77(24):12931-40. PMID: 14645549.
      Citations:    
    71. Belousova N, Korokhov N, Krendelshchikova V, Simonenko V, Mikheeva G, Triozzi PL, Aldrich WA, Banerjee PT, Gillies SD, Curiel DT, Krasnykh V. Genetically targeted adenovirus vector directed to CD40-expressing cells. J Virol. 2003 Nov; 77(21):11367-77. PMID: 14557622.
      Citations:    
    72. Triozzi PL, Kim J, Aldrich W. Infusion of unpulsed dendritic cells derived from granulocyte/macrophage colony-stimulating factor-mobilized peripheral blood CD34+ cells and monocytes in patients with advanced carcinoma. J Hematother Stem Cell Res. 2003 Jun; 12(3):279-87. PMID: 12857369.
      Citations:    
    73. Moulton HM, Yoshihara PH, Mason DH, Iversen PL, Triozzi PL. Active specific immunotherapy with a beta-human chorionic gonadotropin peptide vaccine in patients with metastatic colorectal cancer: antibody response is associated with improved survival. Clin Cancer Res. 2002 Jul; 8(7):2044-51. PMID: 12114402.
      Citations:    
    Triozzi's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (350)
    Explore
    _
    Co-Authors (26)
    Explore
    _
    Similar People (48)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _